ImmunityBio's Q4 Earnings Confirm Growth but Spotlight Unresolved Risks

What happened

ImmunityBio reported Q4 2025 earnings, with net product revenue rising 20% quarter-over-quarter to $38.3 million, continuing the ANKTIVA commercial ramp in the U.S. However, this growth is underpinned by extreme customer concentration, where ~99% of gross revenue comes from just four distributors, signaling vulnerability to inventory swings rather than robust end-demand. The earnings call likely emphasized international progress, including the EU's conditional authorization and a planned Saudi launch, but these expansions have yet to generate material revenue and face regulatory hurdles. Financially, the company remains in a precarious position with negative free cash flow of -$70.4 million in FY2025 and significant overhangs like a $505 million related-party convertible note and a $164.2 million arbitration claim. Despite the positive revenue narrative, these factors underscore that the stock's current valuation at $9.83 may not fully account for potential dilution or operational setbacks.

Implication

The Q4 results show ANKTIVA's commercial traction, but the heavy reliance on a few distributors means revenue could be volatile and not indicative of sustainable demand. International expansions like the EU and Saudi launches offer upside but are conditional and untested, requiring close monitoring for actual revenue contributions. Persistent cash burn and legal overhangs increase the likelihood of dilutive financing, which could erode shareholder value if growth stalls. Key near-term checkpoints include the next quarter's revenue growth without increased concentration and evidence of EU or Saudi monetization. Until these risks de-escalate, the DeepValue report's WAIT rating and attractive entry below $7.50 remain prudent, as the stock already prices in an optimistic ramp.

Thesis delta

The earnings call does not alter the core investment thesis; it confirms the commercial momentum highlighted in the DeepValue report while reiterating that high risks from customer concentration and financial overhangs persist. Investors should wait for concrete signs of de-risking, such as reduced dependency on top customers and tangible international revenue, before reconsidering the WAIT rating.